
Acquisition - August 2, 2019
Norwegian bioinformatics company OncoImmunity acquired by NEC
OncoImmunity will now become a subsidiary of NEC and operate under the name of NEC OncoImmunity AS. OncoImmunity, founded in 2014, is a bioinformatics company dedicated to the development of software solutions that facilitate the effective selection of patients for cancer immunotherapy, and identify optimal neoantigen targets for personalized cancer vaccines and cell therapies in […]

Biotech Business - November 12, 2013
BioGaia plans to invest in project aimed at developing drug for NEC
The board of BioGaia has decided to invest in the first phase of a long-term project aimed at developing a drug with rigorous hygiene, analysis and documentation requirements, to treat the highly fatal disease Necrotising Enterocolitis (NEC), which affects premature infants. BioGaia will invest SEK 42 million in the project over a two-year period. The […]